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enhanced avidity from a 
multivalent fluorescent 
antimicrobial peptide enables 
pathogen detection in a human 
lung model
Ahsan R. Akram  1, Nicolaos Avlonitis2, emma Scholefield1, Marc Vendrell1, Neil McDonald1, 
Tashfeen Aslam2, Thomas H. Craven1, Calum Gray  3, David S. Collie4, Andrew J. Fisher  5, 
Paul A. Corris5, timothy Walsh1, Christopher Haslett1, Mark Bradley1,2 & Kevin Dhaliwal1
Rapid in situ detection of pathogens coupled with high resolution imaging in the distal human lung 
has the potential to provide new insights and diagnostic utility in patients in whom pneumonia is 
suspected. We have previously described an antimicrobial peptide (AMP) Ubiquicidin (fragment UBI29–41) 
labelled with an environmentally sensitive fluorophore that optically detected bacteria in vitro but 
not ex vivo. Here, we describe further chemical development of this compound and demonstrate that 
altering the secondary structure of the AMP to generate a tri-branched dendrimeric scaffold provides 
enhanced signal in vitro and ex vivo and consequently allows the rapid detection of pathogens in situ 
in an explanted human lung. This compound (NBD-UBIdend) demonstrates bacterial labelling specificity 
for a broad panel of pathogenic bacteria and Aspergillus fumigatus. NBD-UBIdend demonstrated high 
signal-to-noise fluorescence amplification upon target engagement, did not label host mammalian cells 
and was non-toxic and chemically robust within the inflamed biological environment. Intrapulmonary 
delivery of NBD-UBIdend, coupled with optical endomicroscopy demonstrated real-time, in situ detection 
of bacteria in explanted whole human Cystic Fibrosis lungs.
Pulmonary bacterial and fungal infection is a common and often fatal event1,2 and pneumonia is a foremost dif-
ferential diagnosis in ventilated and immunocompromised patients who develop rapid respiratory deterioration3. 
Severe pneumonia, the development of ventilator associated pneumonia (VAP) and adult respiratory distress 
syndrome (ARDS) all cause significant morbidity and mortality and are responsible for a large proportion of 
healthcare costs4–6. Current management algorithms7,8 include the retrieval of bronchoalveolar lavage (BAL) or 
endotracheal sampling prior to empirical broad-spectrum antimicrobials, but all methods have variable sensitiv-
ity, are prone to contamination and confer significant time delays for microbial results.
Optical endomicroscopy (OEM) is a promising and attractive diagnostic platform9–12 and our work has 
demonstrated the utility to delineate gram-negative bacteria in mechanically ventilated patients in situ13 through 
an approach involving topically administered microdosed compounds with fiber based OEM. Furthermore, we 
have previously reported14 on the antimicrobial peptide (AMP) Ubiquicidin (UBI29–41) demonstrating that the 
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linear fragment coupled with a fluorophore is insufficient for bacterial imaging in ex vivo lungs due to rapid deg-
radation, despite being utilised as a nuclear medicine imaging agent15.
Here, we describe further development of this compound, engineering a multivalent (tri-branched) form, 
while utilising a modified portion of the bacterial binding fragment (UBI29–41) of the 59 amino acid sequence 
in which the metabolically labile methionine residue in replaced with a norleucine analogue. The arms of the 
trivalent scaffold were capped with the environmentally sensitive fluorophore, 7-nitrobenz-2-oxa-1,3-diazole 
(NBD)16 that self-quenches any residual fluorescence within the aqueous environment and then generates excel-
lent signal-to-noise ratios when dispersed in the distal human lung, with fluorescent amplification only upon 
entry into the hydrophobic environment of the bacterial membrane. When compared to its’ monovalent equiv-
alent, NBD-UBIdend selectively labelled a diverse panel of pathogenic bacteria and Aspergillus fumigatus, and 
remained chemically stable in the complex environment of the inflamed and injured lung. It detected bacteria 
in an ex vivo large animal model of bacterial burden and in infected explanted cystic fibrosis (CF) human lungs.
Results
NBD-UBIdend specifically labels bacteria and fungi with high signal-to-noise ratio over inflam-
matory cells. The multivalent peptide (NBD-UBIdend) comprising three modified monomeric UBI pep-
tides, coupled to the environmentally responsive fluorophore NBD (NBD-UBI) (Fig. 1A) was synthesised by 
solid-phase peptide synthesis (Fig. 1B).
NBD-UBIdend demonstrated fluorescent amplification in vitro with increasing environmental hydrophobicity 
(Fig. 1C). Bacterial labelling was demonstrated in a concentration dependent manner (Fig. 1D) and of a panel of 
clinically relevant lung pathogenic bacteria, including both Gram-positive and Gram-negative species (Fig. 1E) 
with varying labelling intensity (Fig. 1F).
Furthermore, to ensure the compound retains specify and does not label the inflammatory cell infiltrate 
observed with pneumonia, NBD-UBIdend was co-cultured with freshly isolated primary human neutrophils, 
monocytes, lymphocytes and human alveolar macrophages (Fig. 2A–D) with no labelling seen. Confocal imag-
ing was undertaken in the continued presence of the NBD-UBIdend demonstrating the fluorescent amplifica-
tion in bacteria. To further demonstrate selectivity in human lung tissue, bacterial labelling was demonstrated 
Figure 1. NBD-UBIdend displays fluorescence amplification in hydrophobic environments and labels a diverse 
panel of clinically relevant pathogens in a concentration dependent manner. (A) The structure of NBD-UBI 
(monomer). (B) The structure of NBD-UBIdend (multivalent construct). (C) NBD-UBIdend demonstrates 
fluorescence amplification in increasing concentrations of t-butanol mimicking a hydrophobic environment 
(representative plot, n = 3). (D) Fluorescence quantification of P. aeruginosa imaged on a benchtop confocal 
microscope in the continual presence of increasing concentrations of NBD-UBIdend. Images show representative 
images at denoted concentrations of NBD-UBIdend (scale bar represents 5 μm). Each point on the graph 
represents the mean (+/− SEM) of three independent experiments where at least three fields of view were 
quantified with a single site non-linear fit of the data. (E) Representative confocal images of a panel of clinically 
relevant pathogens imaged in the continued presence of NBD-UBIdend (5 μM), scale bar represents 5 μm. P. 
aeruginosa data includes both the laboratory strain (PA01) and a clinical isolate from a patient with VAP 
(J3284). (F) Quantification of fluorescent intensity of bacterial imaging on a benchtop confocal microscope. 
Data shows the mean (+/− SEM) of three independent experiments where at least three independent fields of 
view were assessed.
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Figure 2. NBD-UBIdend demonstrates selectivity for bacteria and A. fumigatus over human cells. (A–C) Co-
culture of (A) freshly isolated human neutrophils, (B) freshly isolated human mononuclear cells and (C) human 
alveolar macrophages retrieved from bronchoalveolar lavage with P. aeruginosa imaged with NBD-UBIdend 
5 µM. Plot profiles quantify fluorescence across the dashed line in the NBD channel and counterstain (Syto-82)  
channel. Each panel shows representative images of at least three independent experiments for each cell type, 
scale bars represent 10 µm. (D) Quantification of benchtop confocal data demonstrating significantly lower 
fluorescence on neutrophils, mononuclear cells and BALF macrophages compared to bacteria. Bars show 
mean fluorescence (+/− SEM) from three independent experiments, where at least three fields of view were 
assessed. Analysis by Students t-test, *p < 0.05, **p < 0.01. (E,F) 3D reconstruction of benchtop confocal 
microscope imaging of (E) human alveolar tissue, incubated with P. aeruginosa and labelled with NBD-UBIdend 
5 µM and (F) human alveolar tissue, incubated with A. fumigatus and labelled with NBD-UBIdend 10 µM. White 
arrows indicate specific labelling of bacteria or germinating fungal hyphae, whereas lung epithelial cells are not 
labelled (blue arrows). Yellow arrows indicate elastin autofluorescence present in the human lung. Images are 
representative of three independent experiments. Scale bars represent 10 µm.
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Figure 3. NBD-UBIdend has greater affinity and demonstrates improved signal-to-noise when labelling bacteria 
in pulmonary surfactant than the linear NBD-UBI and shows stability in ARDS BALF. (A) Quantification of 
retained fluorescence following a wash and re-imaging on a benchtop confocal microscope. Each bacterial 
strain and compound were normalised to their pre-wash fluorescence intensities (bacteria were incubated with 
NBD-UBI at 15 μM or equimolar concentration of NBD-UBIdend at 5 μM). Bars represent means (+/− SEM) 
of independent experiments where at least three fields of view were assessed, and analysed by a Student’s t-test, 
*p < 0.05, **p < 0.01, ***p < 0.001. (B) Representative images of P. aeruginosa imaged in the presence of 
synthetic pulmonary surfactant. Green panels show either NBD-UBI 10 μM or NBD-UBIdend 3.3 μM with red 
panels showing Syto82 counterstaining, purple panels showing synthetic surfactant and phase contrast images 
demonstrating surfactant vesicles. (C) Fluorescence quantification of P. aeruginosa imaged with NBD-UBI 
at 10 μM or NBD-UBIdend at 3.3 μM in the presence of fluorescently labelled high-density surfactant vesicles. 
Data represents the mean fluorescence of the NBD channel on bacteria compared to surfactant and show a 
significantly higher bacteria:surfactant fluorescence intensity for NBD-UBIdend than NBD-UBI. Bars represent 
means (+/− SEM) of three independent experiments where at least three fields of view were assessed, analyses 
by Student’s t-test, **p < 0.01. (D) Stability of compounds in saline and ARDS BALF demonstrating breakdown 
of NBD-UBI in ARDS BALF when analysed by MALDI-TOF MS (left panel) the presence of NBD-UBIdend 
in ARDS BALF when assessed by FTMS (right panel). (E) Representative flow histograms for bacteria when 
incubated with NBD-UBI (grey histograms) at 15 μM or NBD-UBIdend 5 μM (dotted line) demonstrating a 
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by confocal microscopy of human alveolar tissue17. Three-dimensional optical reconstructions confirmed 
bacterial-specific labelling within this complex environment (Fig. 2E).
NBD-UBIdend also labelled the pulmonary pathogenic fungus Aspergillus fumigatus in human lung tissue 
(Fig. 2F). The pattern of labelling of Aspergillus fumigatus, imaged with OEM (Supplementary Fig. S1) was clearly 
discrete from bacteria, supporting the utility of NBD-UBIdend and OEM to discriminate bacteria from Aspergillus 
fumigatus.
NBD-UBIdend demonstrates high avidity, stability when compared to its linear fragment and 
is non-toxic. NBD-UBIdend demonstrated high avidity for bacteria as evidenced by retention of bacterial 
labelling despite washing steps in vitro. Compared to 15 μM of the analogous linear moiety (NBD-UBI), 5 μM 
of NBD-UBIdend retained bacterial labelling after washing (Fig. 3A). Hydrophobic phospholipoprotein compo-
nents of pulmonary surfactant have the potential to generate off-target fluorescence. In order to investigate this, 
synthetic surfactant was co-cultured with bacteria and imaged. NBD-UBIdend labelled bacteria in the presence of 
synthetic surfactant with good signal-to-noise ratios (Fig. 3B,C). Chemical stability was assessed by incubating 
NBD-UBIdend and NBD-UBI with bronchoalveolar lavage fluid (BALF) from ARDS patients in ICU and perform-
ing mass spectroscopic analysis. NBD-UBI was rapidly degraded in ARDS BALF, while NBD-UBIdend remained 
intact (Fig. 3D). Furthermore, the multivalent peptide provided enhanced fluorescent labelling when compared 
to equimolar levels of the analogous monomeric construct NBD-UBI (Fig. 3E,F).
NBD-UBIdend demonstrated no overt biological toxicity, evidenced by absence of erythrocyte hemolysis, and 
no preclinical in vivo toxicity: murine intratracheal instillation of high concentrations (over 700 times greater 
than the final intended human pulmonary dosing), resulted in no pulmonary inflammatory cell recruitment, 
pulmonary toxicity or systemic toxicity at early and late time-points (Supplementary Fig. S2A–D).
NBD-UBIdend rapidly detects bacteria with topical microdosed endobronchial delivery and OEM 
in a large animal ex vivo lung model. Using a previously reported model13 we evaluated NBD-UBIdend 
against a diverse panel of clinically relevant pathogenic bacteria (Fig. 4). NBD-UBIdend was able to label bacterial 
segments, over control segments and the linear NBD-UBI compound within a clinically relevant limit of detec-
tion (LoD) of 1 × 105 CFU/mL bacteria retrieved on BALF (Fig. 4A–F and Videos 1–4). Monomeric NBD-UBI 
failed to detect bacteria (Fig. 4D) in this model.
NBD-UBIdend detects bacteria in situ in whole explanted human lungs. To further support clin-
ical utility, we performed bronchoscopy and delivery of NBD-UBIdend in freshly-explanted whole lungs from 
patients with cystic fibrosis (CF) undergoing transplantation (Fig. 5A). The CF lungs were extremely damaged 
with large amounts of mucopurulent secretions. Discrete distal bronchopulmonary segments were instilled with 
NBD-UBIdend or equimolar monomeric NBD-UBI (negative control). The characteristic bacterial signal of punc-
tate twinkling speckles and also distinct and intense colonies were detected in the alveoli in the NBD-UBIdend 
instilled segments, but not the monomeric instilled segments (Fig. 5B,C and Video 5). BAL confirmed the pres-
ence of pathogenic bacteria in all segments of the CF lung (Fig. 5D). This confirmed the ability of NBD-UBIdend to 
rapidly detect bacteria in situ in the human lung using a microdosing regime and OEM.
Discussion
Immediate-point-of-care bedside methodologies to enable clinicians to determine the presence or absence of 
bacteria or pathogenic fungi in the distal lung are required. Clinicians are faced with significant uncertainty in 
relation to triggers to commence antibiotic treatment7, the choice of agents18 and especially when to de-escalate 
therapy19. These issues are barriers to effective antibiotic stewardship because of the association between delayed 
and inadequate antibiotic therapy and adverse clinical outcomes20.
Optical imaging of bacteria is an emerging and attractive modality21–23 and utilising OEM with localised 
microdosed delivery of SmartProbes in distal bronchopulmonary segments potentially offers an immediate 
method for bacterial detection. This approach shows particular promise for the future as it can be multiplexed 
using fiber based systems capable of multispectral imaging24,25, used in combination with other SmartProbes for 
Gram-negative bacteria13 or inflammatory cells26,27 and compounds can be delivered directly into the imaging 
field of view28. Furthermore, with ongoing refinements to the image analysis algorithms through multiple meth-
ods29–31, automated readouts of the signals generated may help decision making and advance our understanding 
of the pathophysiology during suspected pneumonia.
UBI29–41, in its monomeric form, has been applied in human infection imaging in the form of radionuclide 
imaging with technetium32. We demonstrated that this monomeric scaffold was rapidly degraded in the inflamed 
bronchoalveolar compartment, and have demonstrated that a monomeric ligand remains ineffective for bacterial 
labelling in assays using fragments of human lung tissue14. In contrast, the trivalent dendrimeric scaffold afforded 
enhanced proteolytic stability, partitioning in surfactant and high avidity in the whole human lung.
Although this compound demonstrates promise for clinical utility, it now requires clinical translation to deter-
mine utility alongside other SmartProbes in patients with suspected pneumonia.
greater fluorescence intensity at eqimolar dye concentrations. (F) Quantification of flow cytometry data for 
the monomeric form (white bars, normalised) and dendrimeric forms (grey bars) demonstrating between a 
2–10 fold increase in fluorescence at eqimolar dye equivalents. Bars represent means (+/− SEM) from three 
independent experiments, analysis is by students t-test, **p < 0.01, ***p < 0.001.
6Scientific RepoRts |          (2019) 9:8422  | https://doi.org/10.1038/s41598-019-44804-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
In summary, we have synthesized a multivalent fluorescent UBI analogue that demonstrates excellent optical 
properties for the detection by optical imaging platforms already in clinical use and with microdosed delivery 
selectively labels a range of pathogens in vitro and in an ex vivo ovine model. Importantly, we have also shown 
Figure 4. NBD-UBIdend labels bacteria in situ in an ex vivo ovine lung model of pneumonia. (A) Panels show 
representative images of positive control of GFP S. aureus (upper) or PKH stained S. aureus (lower) instilled 
into an ovine pulmonary segment and imaged demonstrating a characteristic punctate fluorescent bacterial 
signal. (B) Representative images of OEM imaging where control segments (PBS vehicle control) and S. aureus 
segment with monomer NBD-UBI do not show characteristic punctate bacterial signal, whereas S. aureus, 
K. pneumoniae, E. coli and P. aeruginosa with NBD-UBIdend (2 μM) demonstrate in situ bacterial labelling 
when the SmartProbe is applied topically in the distal alveolar space (see also Videos 1–3). (C) Image analysis 
algorithm of entire datasets following the removal of redundant frames. Bars represents the combined mean 
(+/− SEM) of the percentage of frames with over 80 detected dots per frame over the imaging sequence for 
individual experiments. White bars represent NBD-UBI (monomer) with no significant increase for S. aureus 
(n = 6) over PBS control segments (n = 6), ns = not significant. Grey bars demonstrates a significantly higher 
number of detected dots per frame for the bacterial segments (S. aureus n = 8, E. coli n = 6, K. pneumoniae 
n = 8, P. aeruginosa n = 8) when compared to control segment (n = 9) for NBD-UBIdend, *p < 0.05, **p < 0.01, 
***p < 0.001 Students t-test. (D) Performance characteristics to distinguish control segments (PBS instilled, 
n = 9) or bacterial segments (comprising of S. aureus, E. coli, K. pneumoniae or P. aeruginosa, n = 30) with 
NBD-UBIdend demonstrating an area under the curve (95% confidence interval) of 0.9259 (0.8169 to 1.035), 
p = 0.0001280. (E) BALF from ovine segments demonstrating clinically relevant bacterial yields, n = 4 for all 
segments except dilution of P. aeruginosa (PA) where n = 3. Bars represent mean (+/− SEM).
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that this novel technology can specifically detect bacteria in the harsh environment of freshly explanted human 
lungs from patients with CF.
Materials and Methods
Ethics statement. All experiments using human samples were performed following approval of the appro-
priate regional ethics committee (REC), with informed consent of the patients and in accordance with the rele-
vant guidelines and regulations at the University of Edinburgh. BALF for alveolar macrophages: (East of Scotland 
Research Ethics Service REC no: 07/S1102/20), blood for isolation of neutrophils and mononuclear cells: (Lothian 
REC no: 08/S1103/38), human lung tissue: (East of Scotland Research Ethics Service REC no: 13/ES/0126) and 
explant Cystic Fibrosis Lung assessment: (NRES Committee North East-Newcastle & North Tyneside REC no: 
Figure 5. NBD-UBIdend labels colonised bacteria in situ in whole explant Cystic Fibrosis (CF) Human Lungs. 
(A) Experimental procedure of CF lungs with bronchoscopy, Smartprobe instillation, OEM imaging and 
bronchoalveolar lavage retrieval. (B) Representative frames of segments instilled with NBD-UBI (6 µM) 
with minimal punctate signal (upper) and segment instilled with NBD-UBIdend (2 µM) demonstrating the 
characteristic punctate signal associated with bacterial labelling. (C) Analysis of OEM videos with image 
analysis algorithm showing a significantly higher proportion of frames containing >80 dots per frame (bacterial 
infection). Bars represents the combined mean (+/− SEM) of the percentage of frames with over 80 detected 
dots per frame over the imaging sequence for individual segments, **p < 0.01, n = 3 CF patient explants. (D) 
Lavage counts from BALF retrieval for control, n = 3 from two CF lungs and NBD-UBIdend, n = 4 from three CF 
lungs. Bars represent mean (+/− SD) of counts.
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11/NE/0291). Animal experiments were performed under UK Home Office Animals Scientific Procedures Act 
1986 (Project License Number 60/4434) in accordance with the guidelines and regulations at the University of 
Edinburgh and following approval of experimental protocols by the Animal Welfare and Ethical Review Body at 
the University of Edinburgh. Ovine lungs were from ewes destined for cull and were euthanized under Schedule 
1 of Animals (Scientific Procedures) Act 1986.
Chemical synthesis and characterisation. The synthetic procedures and characterization data for all the 
chemical probes is described in the Supplementary Information.
Bacterial culture. Bacterial strains were grown and counterstained as previously described13,14. The following 
bacterial strains were used: Methicillin Resistant S. aureus (ATCC 25923), Methicillin Sensitive S. aureus (ATCC 
252), S. pneumoniae (D39 NCTC 7466), H. influenzae (Clinical Isolate), K. pneumoniae (ATCC BAA1706), E. coli 
(ATCC 25922), A. baumannii (J3433 Clinical Isolate), S. maltophilia (J3270 Clinical Isolate), P. aeruginosa (PA01- 
ATCC 47085 and J3284-clinical isolate) and GFP fluorescent S. aureus (RN6390-Gfp-EryR).
Fungal culture. Aspergillus fumigatus (clinical isolate) was stored in potato glucose agar (Fluka Analytical, 
Gillingham, UK) at 4 °C. A wet harvest of conidia was performed into 1 mL of potato dextrose broth (Fluka 
Analytical, Gillingham, UK) and conidia were counted on a haemocytometer. 1 × 106 conidia were added to 9 mL 
potato dextrose broth and grown overnight in a shaking incubator at 37 °C. Germinating hyphae were washed 
for confocal assays.
Neutrophil and mononuclear cell isolation. Neutrophils and mononuclear cells were isolated from the 
peripheral blood of healthy human volunteers using dextran sedimentation and discontinuous Percoll gradients, 
as previously described33.
MALDI-TOF and FTMS. NBD-UBI or NBD-UBIdend were added to saline or pooled BALF from three 
patients with ARDS incubated for 30 min. ARDS BALF was retrieved from patients in ICU, as previously 
described34. Samples were passed through ZipTip (C-18, 0.2 µL) conditioned with 5 µL MeCN (with 0.1% TFA 
as an additive) followed by 20 µL of H2O. The ZipTip was loaded with the sample, washed and eluted with 5 µL of 
80% aq. MeCN (with 0.1% TFA as an additive). Samples were analysed on a MALDI-TOF (PerSeptive Biosystems 
Voyager DE™STR MALDI-TOF) mass spectrometer, Applied Biosystems, Foster City, CA) or FTMS (Bruker 
Daltonics 12 T SolariX Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR MS)).
Emission spectra. The fluorescence emission of NBD-UBIdend solutions were measured in increasing con-
centrations of t-butanol on a Synergy H1 Multi-Mode Spectrophotometer (BioTek, VT, US) upon excitation at 
450 nm.
Surfactant constituent synthesis. Surfactant vesicles were synthesised by dissolving 5 µg 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 2.5 µg L-α-Phosphatidyl-DL-glycerol sodium salt 
(from egg yolk lecithin; PG) in 500 µl chloroform. The solution was evaporated under nitrogen to form a thin 
lipid film in a round bottom flask and subsequently rehydrated with PBS at 48 °C for 1 hour with continuous 
agitation at 750 rpm to generate multilammelar vesicles (MLV). MLVs were stained with Cellvue Claret dye 
(Sigma-Aldrich, St Louis, MO, USA) and diluted 1:4 for use in confocal experiments.
Haemolysis assay. Performed as previously decribed13. Briefly, erythrocytes (resuspended to 20 vol % in 
PBS) were cultured with varying concentrations of NBD-UBIdend, PBS (negative control) or 0.2% Triton X-100 
(positive control) and incubated at 37 °C for 1 h. Wells were diluted with 150 µl of PBS, centrifuged and absorb-
ance of supernatant read at 350 nm.
Single dose intra-tracheal rodent study. Adult male CD-1 mice aged 8–12 weeks were given direct 
intra-tracheal administration of a single dose of NBD-UBIdend (100 µg) in 50 µl PBS (equivalent to 300 µM) or 
PBS vehicle control. Animals were monitored and then sacrificed at 48 hours or 14 days (n = 3 per group per time 
point). Airway resistance was assessed via whole body plethysmography. Following necroscopy, bronchoalveolar 
lavage fluid (BALF) was harvested via 3 × 0.8 ml PBS flushes of the lung and cytospin slides were prepared and 
stained with Diff-Quick (Thermo Fisher Scientific). BALF cell types were quantified using a light microscope. 
Lung, liver and kidney were removed, fixed and paraffin-embedded. Slides were prepared and stained with hema-
toxylin and eosin.
Confocal imaging and analysis. Imaging and analysis was conducted as previously reported13,14. ‘Green’ 
fluorescence (for NBD) was excited with a dedicated 488 nm line, Syto nuclear acid dyes were excited with a ded-
icated 543 nm line and Cellvue Claret labelled surfactant were excited with a dedicated 633 nm line. For affinity 
assays, following initial imaging, the fluid was aspirated from wells and two gentle washes with PBS were per-
formed. The chamber was re-imaged on benchtop confocal.
Flow cytometry. NBD-UBI or NBD-UBIdend were incubated with bacteria for 5 minutes at 37 °C prior to 
analysis using BD FACSCalibur (Becton Dickenson, San Jose, CA, USA) flow cytometer capturing 50,000 of 
counterstained gated events. Analysis performed with FlowJo version 7.6.5 (TreeStar Inc., Ashland, OR).
Ovine lung model and image analysis. The ovine model and analysis algorithm have been reported 
previously13. Briefly, surplus stock animals, which were destined for cull, had their lungs removed, which were 
ventilated and kept at 37 °C, humidity of 65% and ventilated using a Pressure Controlled Ventilator (Vivo PV 
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403, Breas Medical, Sweden). Segments were bronchoscopically identified and bacteria (or PBS control) instilled. 
After >1 hour segments were re-identified with subsequent SmartProbe instillation and OEM imaging at 
488 nm excitation (Cellvizio Lab, Mauna Kea Technologies) using a 1.5 mm diameter S-1500 fiber (Mauna Kea 
Technologies), followed by BALF retrieval. Frame-by-frame analysis was undertaken13 after removal of redundant 
frames; frames were considered positive if there were >80 dots per frame. Data is presented as the proportion of 
frames over a video sequence containing >80 dots per frame.
Ex vivo cystic fibrosis human lung. Whole explant CF lungs were received fresh from theatre (<1 hour) 
and main the bronchi were identified. Bronchoscopy and suction of the airways was performed prior to instilling 
NBD-UBI/NBD-UBIdend into anatomically distinct distal bronchopulmonary segments. The bronchoscope was 
proximally wedged and the S-1500 fiber passed into distal segments. Following imaging in the distal lung (alveo-
lar regions) as described above, a BAL was undertaken, sample was centrifuged at 200 g for 5 minutes to remove 
erythrocytes and cellular material and was plated for bacterial quantification.
Statistical analysis. All experiments were performed at least three times unless otherwise stated and results 
expressed as mean ± SEM. Data was analysed by Student’s t-test or ANOVA, significance was determined as 
p < 0.05 (GraphPad Prism version 5.01 for Windows, GraphPad Software, San Diego California USA).
Data Availability
The data that support the findings of this study are presented in the published article and any additional data is 
available from the corresponding author upon reasonable request.
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